AACR, AstraZeneca form training partnership

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research and AstraZeneca formed a partnership to help foster the next generation of cancer research scientists and stimulate innovative research in the areas of DNA Damage Response in cancer and Immuno-Oncology. This funding opportunity, funded by a grant of $2.9 million from AstraZeneca, will provide support for 12 meritorious postdoctoral...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login